Publication:
International network for comparison of HIV neutralization assays: the NeutNet report II

Simple item page
dc.contributor.authorHeyndrickx, Leo
dc.contributor.authorHeath, Alan
dc.contributor.authorSheik-Khalil, Enas
dc.contributor.authorAlcamí, José
dc.contributor.authorBongertz, Vera
dc.contributor.authorJansson, Marianne
dc.contributor.authorMalnati, Mauro
dc.contributor.authorMontefiori, David
dc.contributor.authorMoog, Christiane
dc.contributor.authorMorris, Lynn
dc.contributor.authorOsmanov, Saladin
dc.contributor.authorPolonis, Victoria
dc.contributor.authorRamaswamy, Meghna
dc.contributor.authorSattentau, Quentin
dc.contributor.authorTolazzi, Monica
dc.contributor.authorSchuitemaker, Hanneke
dc.contributor.authorWillems, Betty
dc.contributor.authorWrin, Terri
dc.contributor.authorFenyö, Eva Maria
dc.contributor.authorScarlatti, Gabriella
dc.contributor.funderUnión Europea. Comisión Europea
dc.contributor.funderWorld Health Organization (WHO/OMS)
dc.contributor.funderEuroprise
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderFundación para la Innovación y la Prospectiva en Salud en España
dc.contributor.funderFund for Scientific Research (Belgica)
dc.contributor.funderIstituto Superiore di Sanita (Italia)
dc.contributor.funderSwedish Research Council
dc.contributor.funderSwedish International Development Cooperation Agency
dc.contributor.funderBill & Melinda Gates Foundation
dc.date.accessioned2018-12-11T12:34:57Z
dc.date.available2018-12-11T12:34:57Z
dc.date.issued2012-05-09
dc.description.abstractBACKGROUND: Neutralizing antibodies provide markers for vaccine-induced protective immunity in many viral infections. By analogy, HIV-1 neutralizing antibodies induced by immunization may well predict vaccine effectiveness. Assessment of neutralizing antibodies is therefore of primary importance, but is hampered by the fact that we do not know which assay(s) can provide measures of protective immunity. An international collaboration (NeutNet) involving 18 different laboratories previously compared different assays using monoclonal antibodies (mAbs) and soluble CD4 (Phase I study). METHODS: In the present study (Phase II), polyclonal reagents were evaluated by 13 laboratories. Each laboratory evaluated nine plasmas against an 8 virus panel representing different genetic subtypes and phenotypes. TriMab, a mixture of three mAbs, was used as a positive control allowing comparison of the results with Phase I in a total of nine different assays. The assays used either uncloned virus produced in peripheral blood mononuclear cells (PBMCs) (Virus Infectivity Assays, VIA), or Env (gp160)-pseudotyped viruses (pseudoviruses, PSV) produced in HEK293T cells from molecular clones or from uncloned virus. Target cells included PBMC and genetically engineered cell lines in either single- or multiple-cycle infection format. Infection was quantified by using a range of assay read-outs including extra- or intra-cellular p24 antigen detection, luciferase, beta-galactosidase or green fluorescent protein (GFP) reporter gene expression. FINDINGS: Using TriMab, results of Phase I and Phase II were generally in agreement for six of the eight viruses tested and confirmed that the PSV assay is more sensitive than PBMC (p = 0.014). Comparisons with the polyclonal reagents showed that sensitivities were dependent on both virus and plasma. CONCLUSIONS: Here we further demonstrate clear differences in assay sensitivities that were dependent on both the neutralizing reagent and the virus. Consistent with the Phase I study, we recommend parallel use of PSV and VIA for vaccine evaluation.es_ES
dc.description.peerreviewedSíes_ES
dc.description.sponsorshipFunding: The project “NeutNet: Standardisation of HIV neutralization assays to be used in vaccine research and clinical trials” was sponsored by the European Community under grant numbers LSSP-CT-2004-012190, EUROPRISE-Network of Excellence grant number LSHP CT-2006-037611 and NGIN grant number 201433. The WHO/UNAIDS HIV Vaccine Initiative provided partial support for the conduct of the project, including the activities of the Repository, such as preparation and shipment of reagents. Additional support was received from The Bill and Melinda Gates Foundation Collaboration for AIDS Vaccine Discovery (CAVD), and Departamento de DST, Aids e Hepatites Virais, MS-Brasil 147/08. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.es_ES
dc.format.number5es_ES
dc.format.pagee36438es_ES
dc.format.volume7es_ES
dc.identifier.citationPLoS One. 2012;7(5):e36438es_ES
dc.identifier.doi10.1371/journal.pone.0036438es_ES
dc.identifier.e-issn1932-6203es_ES
dc.identifier.issn1932-6203es_ES
dc.identifier.journalPloS onees_ES
dc.identifier.pubmedID22590544es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/6808
dc.language.isoenges_ES
dc.publisherPublic Library of Science (PLOS)es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/FP7/201433/EUes_ES
dc.relation.publisherversionhttps://doi.org/10.1371/journal.pone.0036438es_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.meshAIDS Vaccineses_ES
dc.subject.meshAntibodies, Neutralizinges_ES
dc.subject.meshBiological Assayes_ES
dc.subject.meshFemalees_ES
dc.subject.meshHIV Antibodieses_ES
dc.subject.meshHIV Infectionses_ES
dc.subject.meshHeLa Cellses_ES
dc.subject.meshHumanses_ES
dc.subject.meshMalees_ES
dc.titleInternational network for comparison of HIV neutralization assays: the NeutNet report IIes_ES
dc.typejournal articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublication2fc55aca-54b0-411c-b170-c2149068a902
relation.isAuthorOfPublication.latestForDiscovery2fc55aca-54b0-411c-b170-c2149068a902
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
InternationalNetworkForComparison_2012.pdf
Size:
641.41 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Centro Nacional de Microbiología (CNM)